NeuralCipher AI
EN | TR
SCIENTIFIC HUB

Follow the evidence.

My reading listSource policyTürkçe sürüm
SCIENTIFIC LITERATURE · MED

Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial.

Marano M, Pilotto A, Logroscino G, Stefani A, D'Amelio M, Difruscolo O, Barbagallo M, Barone P, Stocchi F, Kiferle L, Antonini A, Donzuso G, Grimaldi L, Ronga B, Centonze D, Sucapane P, Di Marzio F, Marano P, Mascia MM, Magistrelli L, Gambardella A, Di Lazzaro V, Magliozzi A, Urso D, Pierantozzi M, Davì C, Reggiardo G, Gaglianone M, Nicolini G, Padovani A, CITIPARK Study Group.

Parkinsonism Relat Disord · 2026-07-29

DOI: 10.1016/j.parkreldis.2026.108911PMID: 42561742

Check source for accessMulticenter Study; Randomized Controlled Trial; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundCiticoline is a promising therapeutic option for improving both motor and non-motor symptoms in Parkinson's disease (PD) beyond levodopa and other standard dopaminergic treatments.ObjectivesThe CITIPARK study evaluated the efficacy and safety of citicoline in improving clinical outcomes and quality of life (QOL) in PD patients on dopaminergic therapies.MethodsThe randomized, double-blind, multicenter trial compared citicoline (1000 mg/day intramuscular, two six-week cycles) with placebo for 24 weeks in PD under stable medications. The primary endpoint was change in Movement Disorder Society-Unified PD Rating Scale (MDS-UPDRS) total score; secondary endpoints included motor and non-motor subscores, QOL, clinical global impression (CGI) and safety.ResultsThe study enrolled 485 participants, randomizing 474 (citicoline: 303; placebo: 171). Citicoline significantly increased the likelihood of achieving a minimal clinically important difference compared with placebo (OR 2.06, 95% CI 1.06-3.99; P = 0.031) on the MDS-UDPRS total score in the modified intention-to-treat population. Among secondary outcomes, the citicoline group showed greater improvement in motor function (MDS-UPDRS III -2.97 vs -0.13; p = 0.009) and a greater improvement on CGI -II and CGI-III (3.26 vs 3.59; p = 0.021 and 9.30 vs 10.38; p = 0.018, respectively). AEs occurred in 22.1% and 27.1% of the citicoline and placebo groups, respectively.ConclusionsCiticoline was well tolerated and associated with motor benefits compared with placebo in a highly compliant population. The results suggest a role of citicoline as a safe and possibly effective supportive therapy in PD treated with concomitant dopaminergic agents.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.